The Adalimumab biosimilar market is expanding rapidly as more biosimilar versions of Humira (adalimumab) gain approval and enter the competitive landscape. With the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis, the demand for cost-effective biological therapies is growing. Biosimilars provide an affordable...